

DAFTAR PUSTAKA

1. Leo S De, Lee SY, Braverman LE, Unit E, Sciences C. Hyperthyroidism: Lancet review. *Lancet*. 2016;3,88:906-18.
2. Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves' disease—real life data. *Endocrine*. <http://dx.doi.org/10.1007/s12020-017-1306-5> - Diakses Maret 2023
3. Bhusal1 BPK. Graves Disease In StatPearls Publishing. Treasure Island. <https://www.ncbi.nlm.nih.gov/books/NBK448195/> - Diakses Maret 2023.
4. Mihardja L, Karyana M. Hyperthyroidism in Indonesian community: a mini review. *Endocrinol Int J*. 2019;7:52–3.
5. Kementerian Kesehatan RI. Infodatin: Situasi dan Analisis Penyakit Tiroid. Pusat Data dan Informasi Kementerian Kesehatan RI. Jakarta: Menteri Kesehatan RI; 2015:1-8.
6. Erza. Gambaran frekuensi dan karakteristik kelainan tiroid di RSUP Dr M. Djamil padang periode Januari 2017 – Desember 2017. *J Kedokt dan Kesehat*. 2019;44.
7. Chung JH. Antithyroid drug treatment in graves' disease. *Endocrinol Metab*. 2021;36:491–9.
8. Price S, Wilson L. Patofisiologi: Konsep Klinis Proses-Proses Penyakit, edisi 6. Jakarta: EGC; 2006: 1225–36.
9. Wang PW, Chen IY, Juo SH, Hsi E, Liu RT, Hsieh CJ. Genotype and phenotype predictors of relapse of Graves' disease after antithyroid drug withdrawal. *European Thyroid Journal*. 2012; 1: 251–8.
10. Laurberg P, Nygaard B, Andersen S, Carle A, Karmisholt J, Kerjbjerg A, et al. Association between TSH-receptor autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 patients included in the remission induction and sustenance in the remission induction and sustenance in graves disease study. 2024;1-6
11. Buly L, Utama F, Robikhul Ikhsan M, Yanti V. Hubungan Antara Tanda Dan Gejala Klinis Hipertiroid Dengan Hormon Tiroid Pada Penderita Hipertiroid. <http://etd.repository.ugm.ac.id>- Diakses April 2023.
12. Kelompok Studi Tiroidologi Indonesia. Pedoman pengelolaan penyakit hipertiroid. Bandung; 2017:1-39.

13. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedüs L, et al. American association of Clinical Endocrinologists, American college of endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. *Endocr Pract.* 2016;22:1–60.
14. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of graves' hyperthyroidism. *Eur Thyroid J.* 2018;7:167–86.
15. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid.* 2016;26:1343–421.
16. Vargatu I. Williams Textbook of Endocrinology. Vol. 12, *Acta Endocrinologica*. 2016. 113–39.
17. Decroli E, Manaf A, Syahbuddin S. Immunologic and hormonal effects of propylthiouracil treatment using maintenance dose in Graves' disease. *Acta Medica Indonesiana.* 2014; 46(4): 14–9.
18. Diagne N, Faye A, Ndao AC, Djiba B, Kane BS, Ndong S, et al. Epidemiological, clinical, therapeutic and evolutive aspects of Basedow-Graves disease in the Department of Internal Medicine at CHU Aristide Le Dantec, Dakar. *Pan Afr Med J.* 2016;25:6.
19. García-Mayor R V., Álvarez-Vázquez P, Fluiters E, Valverde D, Andrade A. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value. *Endocrine* <http://dx.doi.org/10.1007/s12020-018-1785-z>. - Diakses Mei 2023.
20. Boundia D, Demba D, Djiby S, Assane NM, Mané DI, Limane BA, et al. Evolution of Graves's Disease: Impact of Socio-Demographic and Clinical Factors in Senegalese Subject. *Open J Intern Med.* 2020;10:160–70.
21. Paulsen F, Waschke J. Sobotta Atlas Anatomi Manusia, Jilid 1. 23th ed. EGC; 2010: 234.
22. Pokhrel B BKGD. Graves Disease. In StatPearls Publishing, Treasure Island. <https://www.ncbi.nlm.nih.gov/books/NBK448195/> - Diakses April 2023.
23. Shahid MA, Ashraf MA SS. Physiology, Thyroid Hormone. In StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK500006/> - Diakses April 2023.

24. Sherwood L. Fisiologi Manusia: dari Sel ke Sistem. Ed 6. Jakarta; Penerbit Buku Kedokteran EGC, 2011. Hal 230-243.
25. Kurniawan LB AM. Indonesian Journal of Clinical Pathology and Medical Laboratory. 2015;304–8
26. National Institute of Health and Care Excellence (NICE). Thyroid disease: assessment and management thyroid function tests. Natl Inst Heal Care Excell. 2019;1–55.
27. Soh SB, Aw TC. Laboratory testing in thyroid conditions - Pitfalls and clinical utility. Ann Lab Med. 2018;39:3–14.
28. Bikle DD. The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status. JBMR Plus. 2021;5:1–10.
29. Djokomoeljanto R. Kelenjar Tiroid, Hipotiroidisme dan Hipertiroidisme. Buku Ajar Penyakit Dalam jilid III . Edisi IV. Juni 2006; 1933—58
30. Means Jh, Littlefield J. Graves' disease. Am Pract Dig Treat. 1948;2:488–93.
31. Niedziela M. Hyperthyroidism in adolescents. Endocr Connect. 2021;10:279–92.
32. Ramos-Leví AM, Marazuela M. Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol y Nutr. <http://dx.doi.org/10.1016/j.endoen.2016.09.005> - Diakses April 2023.
33. Barbesino G, Tomer Y. Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98:2247–55.
34. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, dan Loscalzo J. Harrison's Principles of Internal Medicine. Edisi 19. New York NY, McGraw Hill Education. 2015:62-88.
35. Kotwal A, Stan M. Thyrotropin Receptor Antibodies—An Overview. Ophthal Plast Reconstr Surg. 2018;34:S20–7.
36. Hughes K, Eastman C. Long-term management of hyperthyroidism and hypothyroidism Kiernan. The Royal Australian College of General Practitioners. 2021;50(1):36–42.
37. Shim SR, Kitahara CM, Cha ES, Kim SJ, Bang YJ, Lee WJ. Cancer Risk after Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4:1–14.

38. Teng CJ, Hu YW, Chen SC, Yeh CM, Chiang HL, Chen TJ, et al. Use of Radioactive Iodine for Thyroid Cancer and Risk for Second Primary Malignancy: A Nationwide Population-Based Study. *J Natl Cancer Inst.* 2016;108:1–8.
39. Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. *J Clin Oncol.* 2018;36:1831–9.
40. Teepen, J.C., Curtis, R.E., Dores GM et al. Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States. <https://doi.org/10.1038/s41375-018-0149-2> - Diakses April 2023.
41. Luigi Bartalena MD. Graves' Disease: Complications. In: Feingold KR, Anawalt B, Blackman MR et al. South Dartmouth MA. <https://www.ncbi.nlm.nih.gov/books/NBK285551/?report=reader> – Diakses April 2023
42. Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: A literature review. *Indian Heart J.* <http://dx.doi.org/10.1016/j.ihj.2017.07.004>- Diakses April 2023
43. Abdi H, Amouzegar A, Azizi F. Antithyroid drugs. *Iran J Pharm Res.* 2019;18:1–12
44. Lertwattanak R, Kunavisarut T, Sriussadaporn S. Benefits of Long-Term Continuation of Low-Dose Methimazole Therapy in the Prevention of Recurrent Hyperthyroidism in Graves' Hyperthyroid Patients: A Randomized Prospective Controlled Study. *Int J Endocrinol.* 2022;1-10.
45. Song E, Kim M, Park S, Park MJ, Kim JA, Roh E, et al. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study. *Front Endocrinol.* 2021;12:1–8.
46. Sarr A, Diédhiou D, Ndour-Mbaye NM, Sow D, Diallo IM, Alaoui S El, et al. Graves' Disease in Senegal: Clinical and Evolutionary Aspects. *Open J Intern Med.* 2016;06:77–82.
47. Clinical I, Guidelines P. Indonesian Clinical Practice Guidelines for Hyperthyroidism The Indonesian Society of Endocrinology Diseases, Task Force on Thyroid. *J ASEAN Fed Endocr Soc.* 2012;27(1):34–9.
48. Kanokwongnuwat W, Penpong N, Sangsri C. Incidence and treatment outcomes of Graves' disease in Thailand: a single-center retrospective

observational study. <https://doi.org/10.1186/s13044-022-00142-4> - Diakses September 2023.

49. Ahmed MMA. Outcomes of Long-Term Follow-up of Patients Receiving Antithyroid Medication for Hyperthyroidism due to Graves' Disease. *SJMS* 2023; 2 (2): 54-63.
50. Liu X, Wong CKH, Chan WWL, Tang EHM, Woo YC, Lam CLK, et al. Outcomes of Graves' Disease Patients Following Antithyroid Drugs, Radioactive Iodine, or Thyroidectomy as the First-line Treatment. *Ann Surg*. 2021;273:1197–206.
51. Eliana F, Suwondo P, Asmarinah A, Harahap A, Djauzi S, Prihartono J, et al. The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease. *Acta Med Indones*. 2017;49:195–204.
52. Lasrado N, Jia T, Massilamany C, Franco R, Illes Z, Reddy J. Mechanisms of sex hormones in autoimmunity: Focus on EAE. *Biol Sex Differ*. 2020;11(1):1–14.
53. Wémeau J louis, Klein M, Sadoul JL, Briet C, Vélayoudom-Céphise FL. Graves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factors. *Ann Endocrinol*. 2018;79(6):599–607.
54. Ortona, Elena Pierdominici, Marina Maselli, Angela Veroni, Caterina Aloisi F, Shoenfeld and Y. Sex-based differences in autoimmune diseases. 2016;2:205-212.
55. Magri F, Zerbini F, Gaiti M, Capelli V, Ragni A, Rotondi M, et al. Gender influences the clinical presentation and long-term outcome of graves disease. *Endocr Pract*. 2016;22(11):1336–42.
56. Santin AP, Furlanetto TW. Role of estrogen in thyroid function and growth regulation. *J Thyroid Res*. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113168/> - Diakses Oktober 2023.
57. Bawand R, Borzouei S, Salimbahrami SA, Sheikh V. Comparison of clinical efficacy of antithyroid drugs, radioactive iodine, and thyroidectomy for treatment of patients with graves' disease, toxic thyroid adenoma, and toxic multinodular goiter. *Biomed Biotechnol Res J*. 2022;6(4):569–75.
58. Barrett K, Barman S, Boitano S BH. *Ganong's Review of Medical Physiology*. Review of Medical 25e. New York, NY McGraw-Hil; 2016;4:301-314.

59. Guyton AC HJ. Buku Ajar Fisiologi Kedokteran. 12th ed. EGC, editor. JAKARTA; 2014. 1022 p.
60. Azizi F, Abdi H, Amouzegar A. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial. *BMC Endocr Disord.* 2021;21:1–7.
61. Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, Tsukamoto Y, et al. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in graves' disease: A retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. *Endocr J.* 2011;58(2):95–100.
62. Anagnostis P, Adamidou F, Polyzos SA, Katargari S, Karathanasi E, Zouli C, et al. Predictors of long-term remission in patients with Graves' disease: A single center experience. *Endocrine.* 2013;44(2):448–53.
63. Elsherbiny TM. Characterization, treatment preferences, and outcomes of 390 Egyptian Graves' disease patients: a retrospective study. *Egypt J Intern Med.* <https://doi.org/10.1186/s43162-023-00244-x> - Diakses September 2023.
64. Rajput R, Goel V. Indefinite antithyroid drug therapy in toxic Graves' disease: What are the cons. *Indian J Endocrinol Metab.* 2013;17:88.
65. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Törring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study. *Eur J Endocrinol.* 2008;158:69–75.
66. El-shareif HJ. Clinical Profile and Long-Term Remission in Patients with Graves ' Disease : The Tripoli Medical Centre Experience. 2018;6:1–6.